Home Stock

Stock Research: Aquestive Therapeutics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Aquestive Therapeutics

NMQ:AQST US03843E1047
23
  • Value
    63
  • Growth
    5
  • Safety
    Safety
    36
  • Combined
    23
  • Sentiment
    43
  • 360° View
    360° View
    23
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Aquestive Therapeutics, Inc. is a pharmaceutical company developing orally administered and topical gel products. It operates in the pharmaceutical industry with products like Anaphylm, AQST-108, Libervant, Suboxone, and Emylif, and commercializes its products in the United States and globally through licensees. In the last fiscal year, the company had a market cap of $403 million, profits of $40 million, revenue of $58 million, and 142 employees.

more
Strongest Rank Dividend Yield
Weakest Rank Price vs. Book (P/B)
Country USA
Industry Pharmaceuticals
Size Small
Website aquestive.com
Index
NASDAQ
Aquestive Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
63 49 51 73
Growth
5 31 99 13
Safety
Safety
36 69 40 29
Sentiment
43 50 73 70
360° View
360° View
23 44 93 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
56 85 88 61
Opinions Change
50 50 50 94
Pro Holdings
n/a 49 83 55
Market Pulse
26 21 11 8
Sentiment
43 50 73 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
63 49 51 73
Growth
5 31 99 13
Safety Safety
36 69 40 29
Combined
23 51 83 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
29 15 33 62
Price vs. Earnings (P/E)
42 42 42 42
Price vs. Book (P/B)
98 93 89 92
Dividend Yield
1 1 1 1
Value
63 49 51 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
12 1 55 49
Profit Growth
15 4 91 33
Capital Growth
11 91 81 13
Stock Returns
49 75 95 41
Growth
5 31 99 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
1 74 46 38
Refinancing
60 65 49 43
Liquidity
64 29 31 34
Safety Safety
36 69 40 29

Similar Stocks

Discover high‑ranked alternatives to Aquestive Therapeutics and broaden your portfolio horizons.

Sandisk

NSQ:SNDK
Country: USA
Industry: Technology Hardware & Peripherals
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews